Open AccessCharacterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry
Author(s) -
Brendon M. Patierno,
Wen Chi Foo,
Tyler A. Allen,
Jason A. Somarelli,
Kathryn E. Ware,
Santosh Gupta,
Sandra S. Wise,
John Pierce Wise,
Xiaodi Qin,
Dadong Zhang,
Lingfan Xu,
Yanjing Li,
Xufeng Chen,
Brant A. Inman,
Shan J. McCall,
Jiaoti Huang,
Rick A. Kittles,
Kouros Owzar,
Simon Gregory,
Andrew J. Armstrong,
Daniel J. George,
Steven R. Patierno,
David S. Hsu,
Jennifer A. Freedman
Publication year - 2021
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-021-00460-y
Subject(s) - prostate cancer , medicine , prostate , docetaxel , metastasis , disease , pten , cancer , cancer research , oncology , pathology , biology , apoptosis , genetics , pi3k/akt/mtor pathway
Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficult to establish because of limited specimen availability and poor uptake rates in immunodeficient mice. Ancestrally diverse PCPDXs are even more rare, and only six PCPDXs from self-identified African American patients from one institution were recently made available.